Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that 70 million people in the world's seven major pharmaceutical markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) are affected by irritable bowel syndrome (IBS). However, of the prevalent population of 70 million, only one third of the prevalent population is diagnosed with the disease. According to a new Pharmacor study entitled Irritable Bowel Syndrome, embarrassment, unsympathetic or uninformed physicians, and lack of knowledge about potential treatment options are obstacles for IBS sufferers.

(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )

The study also found that Novartis, GlaxoSmithKline, Solvay, and Alizyme all plan to launch new 5-HT receptor-modulating agents with the potential to treat multiple symptoms, such as altered motility and pain. This class of drugs could account for 58% of major-market sales in 2011.

"The manufacturers of four 5-HT receptor modulators are seeking to capitalize on the significant need for highly effective, multisymptom agents," said Kat Neumeyer, analyst at Decision Resources. "However, fears about safety and tight restrictions on prescribing will significantly hamper the uptake of the 5-HT3 receptor antagonists from GlaxoSmithKline and Solvay, and may have some impact on the use of other IBS-specific therapies in the near term."

Disease Background-Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is the most common of the 25 recognized functional gastrointestinal (GI) diseases--experts estimate that nearly 20% of the world's population suffers from a combination of altered bowel function and abdominal pain that is the hallmark of IBS. Although IBS has attracted the interest of physician and researchers in recent years, the condition was long dismissed as a psychosomatic disorder (or simply a medically inconsequential nuisance). Many IBS sufferers are embarrassed by their GI symptoms and try to self-medicate, and thus go undiagnosed.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies based on primary and secondary research conducted by Decision Resources' on-staff experts. Each comprehensive study assesses a host of market-impacting factors and analyzes the commercial outlook for drugs in research and development. Cardium, Cognos, Immune and Inflammatory Disorders, Infectious Disease, Metabolic Disorders, Psychiatric Disorders, and Onkos concentrate on specific therapeutic areas. Mosaic covers high-interest disease states. Irritable Bowel Syndrome is a Mosaic study.

About Decision Resources

Decision Resources, Inc. is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. The company has provided strategic information services for 30 years, assessing international pharmaceutical and health care industry trends. Visit Decision Resources at www.decisionresources.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563    emarshall@dresources.com 

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION
AP Archive: http://photoarchive.ap.org/
PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,
emarshall@dresources.com

Biotechs Well Ahead of Big Pharma in The Development of Map Kinase-Based Therapeutics

View Now